CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The company develops its products through in-house research programs and partnerships with biopharmaceutical companies and academic researchers. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The company was formerly known as Inception Genomics AG and changed its name to CRISPR Therapeutics AG in April 2014. CRISPR Therapeutics AG was founded in 2013 and is headquartered in Zug, Switzerland.